Top

Published in:

01-02-2003 | Case Report

Generation of CD3⁺CD56⁺ Cytokine-Induced Killer Cells and Their In Vitro Cytotoxicity against Pediatric Cancer Cells

Authors: Suradej Hongeng, Sawang Pctviscs, Surapon Worapongpaiboon, Busaba Rcrkamnuaychoke, Samart Pakakasama, Saengsuree Jootar

Published in: International Journal of Hematology | Issue 2/2003

Title: Generation of CD3+CD56+ Cytokine-Induced Killer Cells and Their In Vitro Cytotoxicity against Pediatric Cancer Cells
Authors: Suradej Hongeng
Sawang Pctviscs
Surapon Worapongpaiboon
Busaba Rcrkamnuaychoke
Samart Pakakasama
Saengsuree Jootar
Publication date: 01-02-2003
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2003
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/BF02983217

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2003

International Comparison of Research Productivity in Hematology

Clinical Significance of Fragmented Red Cells after Allogeneic Bone Marrow Transplantation

Heparin-Induced Thrombocytopenia: Acknowledging Its Presence in Low-Molecular Weight Heparin Therapy

Gray Platelet Syndrome Presenting As Menorrhagia

Clinical Manifestations of Paroxysmal Nocturnal Hemoglobinuria: Present State and Future Problems

Molecular Genetics of Paroxysmal Nocturnal Hemoglobinuria

Keynote webinar | Spotlight on antibody–drug conjugates in cancer